You are here

Home » Content

Sigarayı Bırakmada Antidepresanların Rolü

THE ROLE OF ANTIDEPRESSANTS IN SMOKING CESSATION

Journal Name:

  • Türkiye Aile Hekimliği Dergisi

Publication Year:

  • 2005

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Smoking is the most frequent and preventable cause of premature death. Smoking causes a wide range of disorders, including chronic obstructive pulmonary disease, coronary heart disease, stroke, peripheral vascular disease, peptic ulcer disease and many types of cancer. Worldwide, 3 million people die annualy due to smoking related disorders. Over the last decade, smoking rates have decreased consistently in the general population. It is now widely accepted that nicotine is the principal cause of tobacco consumption, and nicotine preparations are extensively used as aids during smoking cessation. However many of the medical nicotine preperation do not provide to the abstinent smoker an adequate susbstitute for nicotine inhaled in tobacco smoke. As many smokers relapse within a relatively short time, its effective¬ness is disappointing. Sustained-release bupropion is the first non-nicotine pharmacological treatment approved for smoking cessation.
Bookmark/Search this post with
Abstract (Original Language): 
Sigara içme, erken ölümlerin en sık ve önlenebilir nedenidir. Kronik obstrüktif akciğer hastalığı, koroner kalp hastalığı, inme, peri-ferik vasküler hastalıklar, peptik ülser ve çok sayıda kanser sigara içme sonucu meydana gelir. Dünyada her yıl 3 milyon kişi sigara içimiyle ilişkili hastalıklar nedeniyle ölmektedir. Son on yılda genel popülasyonda sigara içme oranı sürekli olarak azalmıştır. Genel olarak nikotinin tütün içiminin temel nedeni olduğu kabul edil¬mekte, tıbbi nikotin preperatları sigara bırakma tedavisinde yaygın olarak kullanılmaktadır. Buna rağmen bir çok medikal nikotin pre-peratı sigara yoksunluğundaki içicilerde nikotinin yerini yeterli de¬recede alamamaktadır. Bir çok sigara içicisinin kısa bir süre içinde tekrar başlaması nedeniyle etkinliği hayal kırıcıdır. Sürekli salınımlı bupropion sigara bırakmakta onaylanmış ilk nikotin dışı farmakolojik tedavidir.
FULL TEXT (PDF): 
PDF icon arastrmx_116859_9_pp_32-36.pdf
  • 1
32-36
  • Turkish

REFERENCES

References: 

1. World Health Organization. Tobacco or health: a global status report. Geneva, World Health Organization, 1997.
2.
Öge
l K, Tamar D, Özmen E ve ark. İstanbul Örnekleminde Sigara Kullanım Yaygınlığı. Bağımlılık 2003; 4: 105-8.
3. Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr, Doll R. Mortality from smoking worldwide. Br Med Bull 1996; 52: 12-21.
4. Henningfield JE, Stapleton JM, Benowitz NL, Grayson RF, London ED.
Higher levels of nicotine in arterial than in venous blood after cigarette smo¬king. Drug Alcohol Depend 1993; 33: 23-9.
5. Benowitz NL. Nicotine addiction. Prim Care 1999; 26: 611-31.
6. Hughes JR. Tobacco withdrawal in self-quitters. J Consult Clin Psychol
1992; 60: 689-97.
7. West RJ, Russell MA, Jarvis MJ, Pizzey T, Kadam B. Urinary adrenaline concentrations during 10 days of smoking abstinence. Psychopharmacology
1984; 84: 141-2.
8. Corrigall WA, Franklin KB, Coen KM, Clarke PB. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychop-
harmacology 1992; 107: 285-9.
9. Benwell ME, Balfour DJ. The effects of acute and repeated nicotine treat¬ment on nucleus accumbens dopamine and locomotor activity. Br J Pharma¬col 1992; 105: 849-56.
10. Epping-Jordan MP, Watkins SS, Koob GF, Markou A. Dramatic decreases in brain reward function during nicotine withdrawal. Nature 1998; 393: 76-9.
11. George TP, O'Malley SS. Current pharmacological treatments for nicotine
dependence. Trends Pharmacol Sci 2004; 25: 42-8.
12. Gritz ER, Nielsen IR, Brooks LA. Smoking cessation and gender: the influence of physiological, psychological, and behavioral factors. J Am Med Wo-mens Assoc 1996; 51: 35-42.
13. Perkins KA, Donny E, Caggiula AR. Sex differences in nicotine effects and self-administration: review of human and animal evidence. Nicotine Tob Res
1999; 1: 301-15.
14. Dorsey J. Control of the tobacco habit. Ann Intern Med 1936; 10: 628-31.
15. Fiore MC. Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline. Respir Care 2000; 45:
1196-9.
16. Glassman AH, Helzer JE, Covey LS ve ark. Smoking, smoking cessation, and major depression. JAMA 1990; 264: 1546-9.
17. Hatsukami D, Huber M, Callies A, Skoog K. Physical dependence on nico¬tine gum: effect of duration of use. Psychopharmacology 1993; 111: 449-56.
18.
Sola
k ZA, Telli CG, Erdinç E. Sigarayı Bırakma Tedavisinin Sonuçları. To-
raks Dergisi 2003; 4: 73-7.
19.
Demi
r T, Tutluoğlu T, Koç N, Bilgin L. Sigara Bırakma Polikiliniğimizin Bir Yıllık Izlem Sonuçları. Tüberküloz ve Toraks 2004; 52: 63-8.
20.
Çan G, Öztuna F, Özlü T. Karadeniz Teknik Üniversitesi Tıp Fakültesi Si¬gara Bırakma Polikliniği Sonuçlarının Değerlendirilmesi. Tüberküloz ve To-
raks 2004; 52: 69-74.
21. Joseph AM, Norman SM, Ferry LH ve ark. The safety of transdermal
ni
¬cotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996; 335: 1792-8.
22. Mahmarian JJ, Moye LA, Nasser GA ve ark. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ische¬mia. J Am Coll Cardiol 1997; 30: 125-30.
23. Dempsey DA, Benowitz NL. Risks and benefits of nicotine to aid smoking cessation in pregnancy. Drug Saf 2001; 24: 277-322.
24. Balfour DJ. The pharmacology underlying pharmacotherapy for tobacco de¬pendence: a focus on bupropion. Int J Clin Pract 2001; 55: 53-7.
25. Ascher JA, Cole JO, Colin JN ve ark. Bupropion: a review of its mecha¬nism of antidepressant activity. J Clin Psychiatry 1995; 56: 395-401.
26. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J
Pharmacol Exp Ther 2000; 295: 321-7.
27. Balfour DJ, Wright AE, Benwell ME, Birrell CE. The putative role of ext-
ra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependen¬ce. Behav Brain Res 2000; 113: 73-83.
28. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related
to addiction. Eur J Pharmacol 2000; 393: 295-314.
29. Delfs JM, Zhu Y, Druhan JP, Aston-Jones G. Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. Nature 2000;
403: 430-4.
30. Golden RN, Rudorfer MV, Sherer MA, Linnoila M, Potter WZ. Bupropion in depression. I. Biochemical effects and clinical response. Arch Gen
Psychiatry 1988; 45: 139-43.
31. Hurt RD, Sachs DP, Glover ED ve ark. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med1997; 337: 1195¬202.
32. Jamerson BD, Nides M, Jorenby DE ve ark. Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo. Clin Ther 2001; 23: 744-52.
33. Covey LS, Sullivan MA, Johnston JA, Glassman AH, Robinson MD, Adams DP. Advances in non-nicotine pharmacotherapy for smoking ces¬sation. Drugs 2000; 59: 17-31.
34. Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D.
A randomized trial of nortriptyline for smoking cessation. Arch Intern Med
1998; 158: 2035-9.
35. Hall SM, Reus VI, Munoz RF ve ark. Nortriptyline and cognitive-behav¬ioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry
1998; 55: 683-90.
36. Edwards NB, Murphy JK, Downs AD, Ackerman BJ, Rosenthal TL.
Doxepin as an adjunct to smoking cessation: a double-blind pilot study. Am J
Psychiatry 1989; 146: 373-6.
37. Dickerson LM, Carek PJ. Nortriptyline effective for smoking cessation. J Fam Pract 2002; 51: 1008.
38. Hennings EC, Kiss JP, Vizi ES. Nicotinic acetylcholine receptor an¬tagonist effect of fluoxetine in rat hippocampal slices. Brain Res 1997; 759:
292-4.
39. Garcia-Colunga J, Awad JN, Miledi R. Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac). Proc Natl Acad Sci USA 1997; 94: 2041-4.
40. Gambassi G, Bernabei R. Antidepressants and smoking cessation. Arch In¬tern Med 1999; 159: 1257-8.
41. Bowen DJ, Spring B, Fox E. Tryptophan and high-carbohydrate diets as ad¬juncts to smoking cessation therapy. J Behav Med 1991; 14: 97-110.
42. Amit Z, Smith BR, Gill K. Serotonin uptake inhibitors: effects on motivat¬ed consummatory behaviors. J Clin Psychiatry 1991; 52(Suppl): 55-60.
43. Levin ED, Briggs SJ, Christopher NC, Rose JE. Sertraline attenuates hyperphagia in rats following nicotine withdrawal. Pharmacol Biochem
Behav 1993; 44: 51-61.
44. Niaura R, Spring B, Borrelli B ve ark. Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment. J Consult Clin Psychol
2002; 70: 887-96.
45. Fowler JS, Volkow ND, Wang GJ ve ark. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996; 379: 733-6.
46. Fowler JS, Volkow ND, Wang GJ ve ark. Brain monoamine oxidase A in¬hibition in cigarette smokers. Proc Natl Acad Sci USA 1996; 93: 14065-9.
47. Berlin I, Said S, Spreux-Varoquaux O ve ark. A reversible monoamine 48. George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O'Malley
oxidase A inhibitor (moclobemide) facilitates smoking cessation and abs- SS. A preliminary placebo-controlled trial of selegiline hydrochloride for
tinence in heavy, dependent smokers. Clin Pharmacol Ther 1995; 58: 444-52. smoking cessation. Biol Psychiatry 2003; 53: 136-43.

Thank you for copying data from http://www.arastirmax.com